3 Stocks Improving Performance Of The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 16,095 as of Wednesday, Nov. 27, 2013, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,757 issues advancing vs. 1,109 declining with 149 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. Top gainers within the industry include HCA Holdings ( HCA), up 1.2%, Intuitive Surgical ( ISRG), up 0.7%, St Jude Medical ( STJ), up 0.9%, Express Scripts ( ESRX), up 0.8% and Covidien ( COV), up 0.5%. On the negative front, top decliners within the industry include DaVita HealthCare Partners ( DVA), down 0.8%, and Boston Scientific ( BSX), down 0.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.68 (1.0%) to $66.45 on average volume. Thus far, 42,588 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 75,700 shares. The stock has ranged in price between $66.39-$66.59 after having opened the day at $66.54 as compared to the previous trading day's close of $65.77.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $11.8 billion and is part of the health care sector. The company has a P/E ratio of 17.4, below the S&P 500 P/E ratio of 17.7. Shares are up 18.6% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Smith & Nephew a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, BioScrip ( BIOS) is up $1.37 (23.2%) to $7.27 on heavy volume. Thus far, 4.8 million shares of BioScrip exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $6.15-$7.42 after having opened the day at $6.15 as compared to the previous trading day's close of $5.90.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. BioScrip has a market cap of $399.1 million and is part of the health care sector. Shares are down 45.6% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates BioScrip as a hold. Among the primary strengths of the company is its robust revenue growth -- not just in the most recent periods but in previous quarters as well. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full BioScrip Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Grifols ( GRFS) is up $0.88 (2.6%) to $34.17 on light volume. Thus far, 109,852 shares of Grifols exchanged hands as compared to its average daily volume of 537,000 shares. The stock has ranged in price between $33.27-$34.17 after having opened the day at $33.42 as compared to the previous trading day's close of $33.29.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $11.4 billion and is part of the health care sector. Shares are up 29.3% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Cramer: Don't Fear the Activist

Cramer: Don't Fear the Activist

European Stocks Rise but London Blue Chips Slip on Stronger Pound

European Stocks Rise but London Blue Chips Slip on Stronger Pound

Take Advantage of U.K. Budget to Bag Some Bargains

Take Advantage of U.K. Budget to Bag Some Bargains